|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
LortetTieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parikh PY and Lillemoe KD: Surgical
management of pancreatic cancer - distal pancreatectomy. Semin
Oncol. 42:110–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rombouts SJ, Vogel JA, van Santvoort HC,
van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG and
Molenaar IQ: Systematic review of innovative ablative therapies for
the treatment of locally advanced pancreatic cancer. Br J Surg.
102:182–193. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gorantla B, Asuthkar S, Rao JS, Patel J
and Gondi CS: Suppression of the uPAR-uPA system retards
angiogenesis, invasion and in vivo tumor development in pancreatic
cancer cells. Mol Cancer Res. 9:377–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sorio C, Mafficini A, Furlan F, Barbi S,
Bonora A, Brocco G, Blasi F, Talamini G, Bassi C and Scarpa A:
Elevated urinary levels of urokinase-type plasminogen activator
receptor (uPAR) in pancreatic ductal adenocarcinoma identify a
clinically high-risk group. BMC Cancer. 11:4482011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khoi PN, Xia Y, Lian S, Kim HD, Kim do H,
Joo YE, Chay KO, Kim KK and Jung YD: Cadmium induces urokinase-type
plasminogen activator receptor expression and the cell invasiveness
of human gastric cancer cells via the ERK-1/2, NF-κB and AP-1
signaling pathways. Int J Oncol. 45:1760–1768. 2014.PubMed/NCBI
|
|
8
|
Kotipatruni RR, Nalla AK, Asuthkar S,
Gondi CS, Dinh DH and Rao JS: Apoptosis induced by knockdown of
uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling
in medulloblastoma. PLoS One. 7:e447982012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhuo J, Tan EH, Yan B, Tochhawng L,
Jayapal M, Koh S, Tay HK, Maciver SK, Hooi SC, SaltoTellez M, et
al: Gelsolin induces colorectal tumor cell invasion via modulation
of the urokinase-type plasminogen activator cascade. PLoS One.
7:e435942012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Knör S, Sato S, Huber T, Morgenstern A,
Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R,
Magdolen V and Seidl C: Development and evaluation of peptidic
ligands targeting tumour-associated urokinase plasminogen activator
receptor (uPAR) for use in alpha-emitter therapy for disseminated
ovarian cancer. Eur J Nucl Med Mol Imaging. 35:53–64. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu D, Overbey D, Watkinson L and Giblin
MF: Synthesis and characterization of an (111) In-labeled peptide
for the in vivo localization of human cancers expressing the
urokinase-type plasminogen activator receptor (uPAR). Bioconjug
Chem. 20:888–894. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daozhen C, Lu L, Min Y, Xinyu J and Ying
H.: Synthesis of (131)
I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin
([(131)I]iodo-17-AAG) and its biodistribution in mice. Cancer
Biother Radiopharm. 22:607–612. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McPherson DW and Knapp FF Jr: A rapid and
simple Sep Pak method for purification of radioiodinated IQNP, a
high affinity ligand for the muscarinic receptor. Nucl Med Biol.
26:859–863. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michl P and Gress TM: Current concepts and
novel targets in advanced pancreatic cancer. Gut. 62:317–326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Persson M, Madsen J, Østergaard S, Jensen
MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M and Kjaer A:
Quantitative PET of human urokinase-type plasminogen activator
receptor with 64Cu-DOTA-AE105: Implications for visualizing cancer
invasion. J Nucl Med. 53:138–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li ZB, Niu G, Wang H, He L, Yang L, Ploug
M and Chen X: Imaging of urokinase-type plasminogen activator
receptor expression using a 64Cu-labeled linear peptide antagonist
by microPET. Clin Cancer Res. 14:4758–4766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Persson M, Madsen J, Østergaard S, Ploug M
and Kjaer A: 68Ga-labeling and in vivo evaluation of a uPAR binding
DOTA- and NODAGA-conjugated peptide for PET imaging of invasive
cancers. Nucl Med Biol. 39:560–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Younes CK, Boisgard R and Tavitian B:
Labelled oligonucleotides as radiopharmaceuticals: Pitfalls,
problems and perspectives. Curr Pharm Des. 8:1451–1466. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lindberg H, Hofström C, Altai M, Honorvar
H, Wållberg H, Orlova A, Ståhl S, Gräslund T and Tolmachev V:
Evaluation of a HER2-targeting affibody molecule combining an
N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at
the C terminus. Tumour Biol. 33:641–651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nock B and Maina T: Tetraamine-coupled
peptides and resulting (99m)Tc-radioligands: An effective route for
receptor-targeted diagnostic imaging of human tumors. Curr Top Med
Chem. 12:2655–2667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spanu A, Farris A, Chessa F, Sanna D,
Pittalis M, Manca A and Madeddu G: Planar scintimammography and
SPECT in neoadjuvant chemo or hormonotherapy response evaluation in
locally advanced primary breast cancer. Int J Oncol. 32:1275–1283.
2008.PubMed/NCBI
|
|
23
|
Cyran CC, Paprottka PM, Eisenblätter M,
Clevert DA, Rist C, Nikolaou K, Lauber K, Wenz F, Hausmann D,
Reiser MF, et al: Visualization, imaging and new preclinical
diagnostics in radiation oncology. Radiation Oncology. 9:32014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gorantla B, Asuthkar S, Rao JS, Patel J
and Gondi CS: Suppression of the uPAR-uPA system retards
angiogenesis, invasion and in vivo tumor development in pancreatic
cancer cells. Mol Cancer Res. 9:377–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
